H.C. Wainwright downgraded Astria Therapeutics (ATXS) to Neutral from Buy without a price target after the company agreed to be acquired by BioCryst (BCRX) for a mix of cash and stock representing an implied value of $13 per share.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- BioCryst price target raised to $26 from $24 at Cantor Fitzgerald
- Astria Therapeutics downgraded to Neutral from Outperform at Wedbush
- BioCryst price target raised to $27 from $17 at Citizens JMP
- Astria downgraded to Market Perform from Outperform at Citizens JMP
- BioCryst reinstated with a Buy at TD Cowen